# The Impact of Omega Three Fatty Acids on Vascular Function in HIV

Study · id `cardio:ct-nct01041521` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01041521](<https://clinicaltrials.gov/study/NCT01041521>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01041521

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.

## Technical summary

Registry record NCT01041521. Randomized; quadruple masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2020-02-11.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 129 participants (enrolled count; ClinicalTrials.gov record NCT01041521, source copy `cardio:ctgov-nct01041521-2020-02-11`, retrieved 2026-10-31)
- Start date: 2010-01 (registry gives no type) (ClinicalTrials.gov record NCT01041521, source copy `cardio:ctgov-nct01041521-2020-02-11`, retrieved 2026-10-31)
- Primary completion: 2014-08 (actual) (ClinicalTrials.gov record NCT01041521, source copy `cardio:ctgov-nct01041521-2020-02-11`, retrieved 2026-10-31)
- Completion: 2015-08 (actual) (ClinicalTrials.gov record NCT01041521, source copy `cardio:ctgov-nct01041521-2020-02-11`, retrieved 2026-10-31)
- Results first posted: 2020-02-11 (ClinicalTrials.gov record NCT01041521, source copy `cardio:ctgov-nct01041521-2020-02-11`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT01041521, source copy `cardio:ctgov-nct01041521-2020-02-11`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01041521-2020-02-11`, retrieved 2026-10-31)

## The registry's words

- Brief title: The Impact of Omega Three Fatty Acids on Vascular Function in HIV
- Acronym: HOST
- Condition: High Triglyceride Level
- Condition: HIV Infection
- Intervention (Drug): Lovaza
- Lead sponsor: Tufts University
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: eb33bc3a2480d8750dd1037e9e16beab71d3a3a5d9636b4ed8e88a7c4f1b39a2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
